Brokerages expect that Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) will post $0.38 earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Maravai LifeSciences’ earnings, with the highest EPS estimate coming in at $0.43 and the lowest estimate coming in at $0.35. Maravai LifeSciences posted earnings of $0.13 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 192.3%. The business is scheduled to issue its next quarterly earnings results on Tuesday, March 1st.
According to Zacks, analysts expect that Maravai LifeSciences will report full year earnings of $1.51 per share for the current financial year, with EPS estimates ranging from $1.49 to $1.52. For the next fiscal year, analysts anticipate that the firm will report earnings of $1.54 per share, with EPS estimates ranging from $1.46 to $1.64. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Maravai LifeSciences.
Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Wednesday, November 10th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.09. The business had revenue of $204.81 million during the quarter, compared to the consensus estimate of $199.68 million. Maravai LifeSciences had a net margin of 22.69% and a return on equity of 109.36%.
Maravai LifeSciences stock opened at $30.33 on Friday. Maravai LifeSciences has a fifty-two week low of $26.81 and a fifty-two week high of $63.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.52 and a current ratio of 6.01. The firm has a 50 day moving average price of $38.80 and a 200 day moving average price of $43.85. The company has a market capitalization of $7.82 billion, a PE ratio of 29.16 and a beta of 0.04.
Large investors have recently made changes to their positions in the stock. Parkside Financial Bank & Trust increased its stake in Maravai LifeSciences by 171.9% in the third quarter. Parkside Financial Bank & Trust now owns 1,153 shares of the company’s stock valued at $57,000 after purchasing an additional 729 shares during the period. Spire Wealth Management acquired a new position in Maravai LifeSciences in the fourth quarter valued at $71,000. American International Group Inc. increased its stake in Maravai LifeSciences by 25.0% in the third quarter. American International Group Inc. now owns 1,994 shares of the company’s stock valued at $98,000 after purchasing an additional 399 shares during the period. SG Americas Securities LLC acquired a new position in Maravai LifeSciences in the second quarter valued at $110,000. Finally, AGF Investments LLC acquired a new position in Maravai LifeSciences in the second quarter valued at $118,000. Hedge funds and other institutional investors own 50.31% of the company’s stock.
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
See Also: What is an economic bubble?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.